Neurol. praxi. 2009;10(6):356-359
Treatment of dystonias
- Centrum pro abnormní pohyby a parkinsonizmus, Brno, I. neurologická klinika LF MU a FN u sv. Anny Brno
Dystonia is characterized by sustained muscle contractions frequently causing repetitive twisting movements or abnormal postures.
Based on the distribution of the symptoms, we classify the dystonias as focal, segmental, multifocal and generalized. Majority of dystonic
syndromes is idiopathic, differential diagnosis of the secondary forms of dystonias is always needed. There is increasing knowledge
about the genetics of dystonias lately. Treatment of dystonias was regarded as complicated and limited. The various drugs were used
(antiepileptic, cholinergic, dopaminergic as well as antidopaminergic drugs) were introduced in the treatment with limited efficacy and
increased side effects. Some patients underwent surgical procedures (selective peripheral denervation and myectomy, dorsal rhizotomy,
stereotactic lesions in the basal ganglia) with different outcome. Botulinum toxin A is currently the treatment of choice in the management
of focal dystonias. Botulinum toxin B is reserved for patients with botulinum toxin A failure (the occurence of the antibodies against
botulinum toxin A). Deep brain stimulation is more widely used for generalized dystonias and focal dystonias refractory to botulinum
toxin treatment when indication criteria were met.
Keywords: botulotoxin, DBS, dystonia, levodopa, tetrabenazine
Published: January 1, 2010 Show citation
References
- Adam OR, Jankovic J. Treatment of dystonia. Park Rel Dis 2007; 13: S362-S368.
Go to original source... 
Go to PubMed... - Albanese A, Barnes MP, Bhatia KP, Fernandez-Alvarez E, Filippini G, Gasser T, Krauss JK, Newton A, Rektor I, Savoiardo M, Valls-Sol? J. A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force. Eur J Neurol 2006; 13(5): 433-444. Go to original source... Go to PubMed...
- Bareš M, Kaňovský P, Muchová M. Grafospasmus (písařská křeč): dlouhodobá léčba botulotoxinem A. Čes Slov Neurol Neurochir 2002; 65/98(4): 240-244.
- Bareš M, Rektorová I, Baláž M, Streitová H, Minks E, Kaňovský P, Rektor I. Long term treatment of cervical dystonia with botulinum toxin: A retrospective assessment of the clinical and quality of life impact. Neurology 2007; 68(Suppl.1): A381.
- Hallett M. Pathophysiology of dystonia. In: Hallett M, Poewe W (eds): Therapeutics of Parkinson´s disease and other movement disorders. Wiley-Blackwell 2008: 205-216. Go to original source...
- Jankovic J. Treatment of dystonia. Lancet Neurol 2006; 5: 864-872. Go to original source... Go to PubMed...
- Kaňovský P, Bareš M, Streitová H, Pospíšilová D, Dufek M. Socioekonomické aspekty terapie faciálních dyskinezí botulotoxinem A. Čes Slov Neurol Neurochir 1996; 3: 148-151.
- Kaňovský P, Streitová H, Daniel P, Hekerlová R, Bareš M, Dufek J. Dlouhodobá remise cervikální dystonie navozená léčbou botulotoxinem A-signál možného ovlivnění centrálního dystonického mechanizmu? Čes Slov Neurol Neurochir 1997; 3: 126-137.
- Kaňovský P, Streitová H, Bareš M, Hortová H. Treatment of facial and orolinguomandibular tardive dystonia by botulinum toxin A: Evidence of a long-lasting effect. Mov Disord 1999; 14(5): 886-888. Go to original source... Go to PubMed...
- Kaňovský P, Bareš M, Streitová H, Klajblová H, Daniel P, Rektor I. Abnormalities of cortical excitability and cortical inhibition in cervical dystonia. Evidence from somatosensory evoked potentials and paired transcranial magnetic stimulation. J Neurol 2003; 250: 42-50. Go to original source... Go to PubMed...
- Kaňovský P, Gaillyová R, Bareš M..Genetika dystonií. Čes Slov Neurol Neurochirur 2003; 66/99: 323-328.
- Kaňovský P, Hekerlová R. Cervikální dystonie a její léčba. Maxdorf, Jesenius: 1997: 84 stran.
- Kartha N. Dystonia. Clin Geriatr Med 2006; 22: 899-914. Go to original source... Go to PubMed...
- Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 2007; 193-197. Go to original source... Go to PubMed...
- Klein C, Ozelius LJ. Dystonia: clinical features, genetics, and treatment. Cur Opin Neurol 2002; 14(4): 491-497. Go to original source... Go to PubMed...
- Murase N, Rothwell JC, Kaji R, Urushihara R, Nakamura K, Murayama N, Igasaki T, Sakata-Igasaki M, Mima T, Ikeda A, Shibasaki H. Subthreshold low-frequency repetitive transcranial magnetic stimulation over the premotor cortex modulates writer's cramp. Brain. 2005; 128(Pt 1): 104-115. Go to original source... Go to PubMed...
- Priori A, Pesenti A, Cappellari A, Scarlato G, Barbieri S. Limb immobilization for the treatment of focal occupational dystonia. Neurology. 2001; 57(3): 405-409. Go to original source... Go to PubMed...
- Schwarz CS, Bressman SB. Genetics and treatment of dystonia. Neurol Clin 2009; 27(3): 697-718. Go to original source... Go to PubMed...
- Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallett M, Jankovic J, Karp B, Ludlow CL, Miyasaki JM, Naumann M, So Y; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70(19): 1699-1706. Go to original source... Go to PubMed...
- Wissel J, Kaňovský P, Růžička E, Bareš M, Hortová H, Streitová H, Jech R, Roth J, Brenneis C, Müller J, Schnider P, Auff E, Richardson A, Poewe W. Efficacy and safety of a standardised 500 unit of Dysport(R) (Clostridium botulinum type A haemaglutinin complex) in a heterogenous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group study. J Neurol 2001; 248(12): 1073-1078. Go to original source... Go to PubMed...